Cargando…

A Novel Curcumin-Based Drug Powder Inhalation Medicine for Chronic Obstructive Pulmonary Disease

The dry powder inhaler is a new form of drug delivery that is widely used as an alternative to traditional drug delivery methods, addressing the shortcomings of traditional drug delivery methods and obtaining better therapeutic results. This mode of delivery is also one of the most rational ways to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Qin, Jiang, Yongjie, Chen, Jing, Wang, Xueling, Zheng, Jiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648444/ https://www.ncbi.nlm.nih.gov/pubmed/34880911 http://dx.doi.org/10.1155/2021/8001787

Ejemplares similares

Retracted: A Novel Curcumin-Based Drug Powder Inhalation Medicine for Chronic Obstructive Pulmonary Disease
por: and Applications, Bioinorganic Chemistry
Publicado: (2023)

Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA(®) Dry Powder Inhaler
por: Prime, David, et al.
Publicado: (2015)

Inappropriate Peak Inspiratory Flow Rate with Dry Powder Inhaler in Chronic Obstructive Pulmonary Disease
por: Chen, Shih-Yu, et al.
Publicado: (2020)

Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers
por: Zhang, Tongtong, et al.
Publicado: (2018)

Aggregated Nanotransfersomal Dry Powder Inhalation of Itraconazole for Pulmonary Drug Delivery
por: Hassanpour Aghdam, Mehdi, et al.
Publicado: (2016)

Development and Evaluation of Paclitaxel and Curcumin Dry Powder for Inhalation Lung Cancer Treatment
por: Lee, Wing-Hin, et al.
Publicado: (2020)

The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries
por: Lewis, A., et al.
Publicado: (2016)

Correct use and ease of use of a placebo dry powder inhaler in subjects with asthma and chronic obstructive pulmonary disease
por: Feldman, Gregory J, et al.
Publicado: (2018)

Knowledge and practice of dry powder inhalation among patients with chronic obstructive pulmonary disease in a regional hospital, Nepal
por: Baral, Mira Adhikari
Publicado: (2018)

Correct use and ease-of-use of placebo ELLIPTA dry-powder inhaler in adult patients with chronic obstructive pulmonary disease
por: Siler, Thomas M., et al.
Publicado: (2022)

Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters
por: Malmberg, L Pekka, et al.
Publicado: (2010)

Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
por: Hawken, Natalia, et al.
Publicado: (2017)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease
por: Janson, Christer
Publicado: (2020)

The future of inhalation therapy in chronic obstructive pulmonary disease
por: Cazzola, Mario, et al.
Publicado: (2022)

Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers
por: Acosta, Maria F., et al.
Publicado: (2020)

Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: An observational comparative study
por: Ramadan, Wijdan H, et al.
Publicado: (2017)

Pulmonary Talcosis Due to Daily Inhalation of Talc Powder
por: Verlynde, Guillaume, et al.
Publicado: (2018)

Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization
por: Momin, Mohammad A. M., et al.
Publicado: (2021)

An evaluation of the use of inhalers in asthma and chronic obstructive pulmonary disease
por: Çakmaklı, Seçil, et al.
Publicado: (2023)

The Impact of Inhaled Corticosteroids on the Prognosis of Chronic Obstructive Pulmonary Disease
por: Park, Ji Won, et al.
Publicado: (2023)

Chronic obstructive pulmonary disease caused by inhalation of dust: A meta-analysis
por: Peng, Cong, et al.
Publicado: (2020)

Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma
por: Hua, Jian-lan, et al.
Publicado: (2021)

Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease
por: Leaker, Brian R., et al.
Publicado: (2019)

Curcumin effects on chronic obstructive pulmonary disease: A systematic review
por: Safari, Saeid, et al.
Publicado: (2023)

Silicosis Caused by Chronic Inhalation of Snail Shell Powder
por: Jung, Jae Woo, et al.
Publicado: (2012)

Aspergillus infection in chronic obstructive pulmonary diseases
por: Guo, Liang, et al.
Publicado: (2023)

Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis
por: Puhan, Milo A, et al.
Publicado: (2009)

An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease
por: Singh, Sonal, et al.
Publicado: (2010)

Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease—The Shifting Treatment Paradigm
por: Wilkie, Morven, et al.
Publicado: (2015)

Altered deposition of inhaled nanoparticles in subjects with chronic obstructive pulmonary disease
por: Jakobsson, Jonas K F, et al.
Publicado: (2018)

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
por: Tashkin, Donald P, et al.
Publicado: (2018)

Personalizing Selection of Inhaled Delivery Systems in Chronic Obstructive Pulmonary Disease
por: Mahler, Donald A., et al.
Publicado: (2023)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease
por: Bajwa, Abubakr A., et al.
Publicado: (2017)

Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems
por: Mehta, Piyush
Publicado: (2016)

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease
por: Kosoglou, Teddy, et al.
Publicado: (2013)

Pulmonary availability of isotretinoin in rats after inhalation of a powder aerosol
por: Raleigh, S M, et al.
Publicado: (2000)

Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery
por: Rashid, Md Abdur, et al.
Publicado: (2019)

Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization
por: Rashid, Md Abdur, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b0hd6v4u6pv2mrdofhoo4dhq8m